Explore

Trendline Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026, Highlighting Scientific Innovations

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026, Highlighting Scientific Innovations

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026, Highlighting Scientific Innovations
Trendline Trendline
Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026

Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026

Exelixis to Present Key Findings on Cancer Treatments at ASCO 2026
Trendline Trendline
Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026

Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026

Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026
Trendline Trendline
NICE Reverses Decision on Genmab's Cervical Cancer Drug Tivdak

NICE Reverses Decision on Genmab's Cervical Cancer Drug Tivdak

NICE Reverses Decision on Genmab's Cervical Cancer Drug Tivdak
Trendline Trendline
Lilly and Novo Nordisk Weight-Loss Drugs Show Potential Cancer Benefits

Lilly and Novo Nordisk Weight-Loss Drugs Show Potential Cancer Benefits

Lilly and Novo Nordisk Weight-Loss Drugs Show Potential Cancer Benefits
Trendline Trendline
NICE Reverses Decision on Genmab's Tivdak for Cervical Cancer Patients

NICE Reverses Decision on Genmab's Tivdak for Cervical Cancer Patients

NICE Reverses Decision on Genmab's Tivdak for Cervical Cancer Patients
Trendline Trendline
GSK Initiates Negotiations with Canadian Alliance for Multiple Myeloma Treatment

GSK Initiates Negotiations with Canadian Alliance for Multiple Myeloma Treatment

GSK Initiates Negotiations with Canadian Alliance for Multiple Myeloma Treatment
Trendline Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Trendline Trendline
FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment
Trendline Trendline
Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment

Myosin Therapeutics Begins Phase 1/2 Trial of MT-125 for Glioblastoma Treatment
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Trendline Trendline
858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment